The prevalence of human cytomegalovirus (HCMV) pp65-, pp150-, IE1-exon4-, gB-and pp28-specific cytotoxic T lymphocyte (CTL) responses was compared among 34 healthy individuals, grouped by neutralizing antibody titers. Moderately and highly seropositive donors showed predominantly pp65-and IE1-exon4-specific CTL responses (92% and 76% of the donors, respectively), with similar precursor frequencies in the 2 donors tested. In addition, highly seropositive and a few moderately seropositive donors showed CTL responses to gB and pp150 (33% and 30% of the donors, respectively). No individual recognized pp28 as a target in the CTL assay. Phenotypic analysis revealed a mixed effector population of CD4 + and CD8 + (1 donor) or only CD8 + cells for pp65-specific effectors (2 donors). IE1-exon4-and pp150-specific effectors were CD8 + (2 donors and 1 donor, respectively), whereas gBspecific CTLs were CD4 + (1 donor). These data may help to design a cellular immunity-based vaccine effective against HCMV diseases.
in bone marrow and renal transplant recipients correlates directly with protection from CMV disease [6] [7] [8] [9] . Thus, an effective HCMV vaccine will probably need to induce a specific CTL response.
Studies to identify which HCMV antigens might be important for immunity have shown that the lower matrix protein pp65 is the immunodominant target for HCMV-specific CTLs [8, [10] [11] [12] [13] . Indeed, high pp65-specific CTL precursor frequencies were shown in seropositive donors [12, 13] . Epitope specificity of pp65-specific CTLs and the presenting HLA alleles were also identified in some donors [11, 12, 14] . HCMV IE1-, pp150-, gB-, and/or gH-specific CTLs have also been detected in studies, but the data are scarce, and the prevalence of proteinspecific CTLs remains controversial [8, 12, 13, [15] [16] [17] [18] [19] [20] . To our knowledge, the only study to examine CTL responses specific to pp28, which is a potent inducer of antibody production [21] , reported the absence of these CTLs in all 4 seropositive donors tested [13] . At least some of the conflicting results might rest in the haplotype differences that affect antigen presentation in different racial groups and in the dominance of CTL epitope variations in HCMV strains in one geographical area but not in another.
In the present study, we compared the prevalence of IE1-exon4-, pp65-, pp150-, gB-and pp28-specific CTLs in a randomly selected population of 34 donors, representing a large panel of naturally seropositive, racially and geographically divergent, HLA-typed donors. We were especially interested in the nonstructural IE1-exon4 protein, which is abundantly expressed very early after infection (earlier than pp65) and con- tinues to be expressed throughout the replicative cycle, making it an attractive vaccine candidate antigen together with pp65 for CTL induction.
Materials and Methods
Study population. Thirty-four healthy adults enrolled in the blood donor program of the Wistar Institute (Philadelphia, PA) and the Albert Szent-Gyorgyi University (Szeged, Hungary) were studied. The group was composed of 12 blacks, 1 Chinese, 1 Japanese, and 20 whites (age range, 22-60 years). HCMV seropositivity was determined by microneutralization assay [22] , where sera with a neutralizing antibody (NA) titer !12 were considered negative, with an NA titer of 1 : 12 to 1 : 96 were "moderately" seropositive, and with an NA titer у1 : 128 were "highly" seropositive. Seropositivity was confirmed by standard ELISA by use of purified HCMV as a coating antigen and lysates of uninfected MRC-5 cells as a control antigen. For each serum dilution, optical density (OD) values obtained in control antigen-coated wells were subtracted from those obtained in HCMV antigen-coated wells. Sera with HCMV-specific OD values у0.2 than the reference negative serum, at a dilution of 1 : 100, were considered positive. Peripheral blood mononuclear cells (PBMC) were typed for major histocompatibility complex (MHC) class I and class II antigens by standard complement-mediated cytotoxicity assay and by polymerase chain reaction (PCR) testing, which were performed by the Immunology and Histocompatibility Laboratory of the Hospital of the University of Pennsylvania, Philadelphia, and by the Blood Transfusion Center at the Albert Szent-Gyorgyi University. Table  1 lists the characteristics of each donor.
Viruses. Human CMV strain Towne was propagated and titered on MRC-5 cells (obtained from Coriell, Camden, NJ) in monolayers. HCMV stocks were stored at Ϫ70ЊC.
The pp65 gene was PCR amplified by use of genomic HCMV DNA as a template (Towne strain) and cloned as described elsewhere [23] . The IE1-exon4 gene (AD169 strain) was amplified by PCR from the pJD083 plasmid [24] . The pp150 and pp28 genes were amplified from HCMV genomic DNA (Towne strain) by PCR.
For restimulation of CTL effector cells in vitro, canarypox recombinants that express individual HCMV proteins were used. The gB-expressing canarypox recombinant has been described elsewhere [25] . pp65, pp150, IE1-exon4, and pp28 canarypox recombinants were constructed by placing these genes under the control of a vaccinia virus promoter in a canarypox donor plasmid, from which a nonessential gene was specifically deleted, as described elsewhere [25] .
The WR strain of vaccinia virus (Vac-WR) and Vac-WR-based recombinants (Vac-gB, Vac-pp65, Vac-IE1, and Vac-pp28) that encode HCMV proteins were used for infection of target cells in cytotoxicity assays. The WR-gB recombinant (Vac-gB) was derived in the WR L variant vaccinia virus by use of previously described methods [26, 27] . WR-pp65, IE1-exon4, and pp28 recombinants (Vac-pp65, Vac-IE1, and Vac-pp28) were derived by use of a hostrange selection system [27] Effector cells. PBMC were separated from freshly drawn heparinized venous blood by centrifugation on Ficoll-Paque (Pharmacia, Piscataway, NJ) density gradients. Our preliminary results showed no difference between fresh or cryopreserved effector cells in their CTL activity; thus, fresh or cryopreserved PBMC were stimulated in vitro with autologous PBMC expressing HCMV proteins in the bulk CTL assays. Stimulator cells were prepared by infecting PBMC with canarypox virus vectors that encode HCMV pp65, IE1-exon4, gB, pp150, or pp28 at a multiplicity of infection (MOI) of 5. After a 1-h incubation, stimulator cells, infected separately with the canarypox virus constructs or with control parental canarypox virus, were washed and mixed with responder PBMC at a responder-to-stimulator ratio of 5 : 1. The mixture of responder and stimulator cells was placed in 24-well plates at cells/ 6 3.5 ϫ 10 2 mL medium/well. The culture medium was RPMI 1640 (Mediatech Cellgro, Herndon, VA), supplemented with 10% FCS (Hyclone, Logan, UT, or Cansera Atlanta Biologicals, Norcross, GA), 4 mM L-glutamine (Sigma, St. Louis), 60 mg/mL gentamicin (Sigma), and 5 mM 2-mercaptoethanol (Sigma). PBMC cultures were supplemented with 330 U/mL interleukin (IL)-7 (R&D Systems, Minneapolis, MN) at the start of culture, and with 20 U/mL IL-2 (Genzyme, Cambridge, MA) on days 4 and 8. Cell lines were tested for CTL activity between days 8 and 13 of culture.
Restimulation of PBMC with HCMV-infected autologous monocytes. Monocytes were separated from PBMC by plastic adherence:
PBMC were incubated on 96-well plates for 1 h at 6 30 ϫ 10 37ЊC, nonadherent cells were aspirated, and plates were washed 3 times with warm medium. Adherent cells were infected with HCMV (MOI, 2-4 plaque-forming units per cell). After a 3-h virus adsorption, cells were washed with medium, and PBMC were added as responder cells (responder-to-stimulator ratio, 4 : 1). pp65-and IE1-exon4-specific lysis were tested after 8 days of in vitro restimulation by use of vaccinia recombinant-infected target cells.
Infection and labeling of target cells. Each of 5 individual HCMV protein-expressing vaccinia recombinants was used to infect -B-LCL (MOI, 10) for 1 h. Cells were diluted 6 6 2 ϫ 10 6 ϫ 10 to 10 6 /1.5 mL with culture medium and were incubated an additional 16 h, washed, and labeled with 100 mCi of 51 Cr-NaCrO 4 (Amersham, Arlington Heights, IL) for 1 h. Labeled cells were washed 3 times before assay.
Cytotoxicity assays. Cytolytic activity of antigen-driven effectors that are present in bulk cultures established from PBMC was measured in a 4-h 51 Cr-release assay. Nonadherent effector cells were collected, washed once, and plated in triplicate roundbottomed 96-well microtiter plates at effector-to-target ratios (E : T) indicated for individual experiments. Targets were autologous B-LCL or heterologous B-LCL or B-LCL matched with effectors in a single HLA class I allele. Chromium release was measured in a gamma counter (Cobra II Packard Instrument, Meriden, CT). Percentage-specific lysis was determined as follows:
release-spontaneous release)/(maximal release-100 ϫ (experimental spontaneous release). For each target, spontaneous release was determined from wells containing medium only, and maximal release was calculated from wells containing 1% NP-40. Spontaneous release was always !30%. Effector cells were considered positive for CTL activity if the percentage specific lysis of test wells was у10% above background lysis (cytotoxicity directed at WT-Vac-infected autologous target cells). Nonspecific background cytolysis was reduced by adding a 30-fold excess of unlabeled, WT-Vac-infected target cells to each well of the 51 Cr-release assay. Limiting dilution assay. Fresh effector PBMC were plated at different cell numbers in 30 replicate wells and were cultured with g-irradiated (3000 rad delivered by an MKA model 68A irradiator; Shepherd, Glendale, CA) autologous PBMC as feeder cells ( /PBMC per well) and with autologous EBV-trans- 4 3 6 ϫ 10 4 ϫ 10 formed lymphoblasts infected with Vac-pp65 or Vac-IE1 for 6-16 h, g irradiated (3000 rad), and ultraviolet irradiated (10 min at a distance of 25 cm with a germicidal lamp) as stimulator cells. After 12-14 days, pp65-or IE1-specific CTL activity of each well was determined on autologous Vac-pp65-or Vac-IE1-infected, autologous WT-Vac-infected, and HLA-mismatched Vac-pp65-or Vac-IE1-infected target cells. CTL precursor frequency was estimated as the input cell number that resulted in 37% negative cultures against the pp65-or IE1-specific target [28] . 51 Cr-release in each well was considered significant at 13 SD above mean lysis observed in control wells (containing only feeder and stimulator cells).
Determination of CTL phenotype. Bulk CTL cultures were established from PBMC. After 8-13 days of culture in vitro, effector ϩ lymphocytes by anti-CD4 (C ), or of MAb ϩ complement CD8 ϩ lymphocytes by anti-CD8 , or of both CD4 ϩ and MAb ϩ C CD8 ϩ by both . Antibodies were from Caltag Labantibodies ϩ C oratories (Burlingame, CA) and were used at a predetermined concentration (16 mg/mL). Nontoxic rabbit complement was from Accurate (Westbury, NY) and was used at a final dilution of 1 : 10. Effector cells were incubated with the antibodies at 4ЊC for 45 min. After washing with medium, cells were further incubated with complement for 30 min at 37ЊC, washed, and resuspended in the predepletion volume of medium so that nondepleted cells would remain at the original concentration, and CMV antigen-specific lysis was determined in a 4-h 51 Cr-release assay. Statistical analysis. Linear regression analysis was done on results of limiting dilution assays (LDAs). Precursor frequency was determined by solving the equation of the best-fit line where the fraction of nonresponding wells equaled 0.37.
Results

CTL responses to pp65, IE1-exon4, gB, pp150, and pp28 in HCMV-seropositive donors.
PBMC were either separated from fresh heparinized blood or reconstituted after cryopreservation, and effector cells were restimulated by individual HCMV antigen-expressing canarypox recombinants. Lytic activity of restimulated memory CTLs was tested in antigen-specific 51 Cr-release assays. The seronegative donors tested showed no CTL activity against the HCMV antigens. CTLs specific for pp65 and IE1-exon4 proteins were detected in 92% and 76% of the seropositive donors, respectively, whereas gB-and pp150-specific CTLs were identified in 33% and 30% of the seropositive donors tested, respectively; no pp28-specific lysis of target cells was detected in any individual (table 1). The number of PBMC obtained from the blood of 4 donors (KL, H-P, H-47, and H-48) was sufficient for testing only pp65-or pp65-and IE1-specific CTLs; therefore, we cannot exclude the presence of CTLs specific for CMV antigens other than pp65 and IE1. Of the volunteers tested for 4 or 5 different CMV antigens, 5 (TK, MT, H-35, H-36, DF) were positive for 4 antigens (pp65, IE1-exon4, gB, and pp150). As shown in figure 1, for 1 of these donors (H-36), the autologous target cells infected with Vacpp65, Vac-IE1, Vac-gB, or Vac-pp150 showed significant lysis at E : T ratios of 40 : 1, whereas autologous WT-Vac-infected and HLA-mismatched (not shown) Vac-recombinant-infected target cells were not lysed, indicating that the cytotoxic response was MHC restricted. No CMV antigen-specific lysis of target cells was detected when PBMC from the same donor were restimulated in vitro with parental canarypox-infected autologous PBMC (not shown). Two donors (BK and H-33) were positive for 3 antigens (pp65, IE1-exon4, and gB or pp150); 9 donors showed double-CTL specificity (pp65 and gB in donor GE; pp65 and IE1-exon4 in donors H-6265, H-22, MBM, BJ, H-23, CK, KI, and H-49); and 6 donors showed single specificity (H-6226, H-34, H-12, NJ, MA, and BI). Of these latter 6 donors, 2 highly seropositive donors (H-12 and NJ) exhibited only IE1-exon4-specific CTLs; repeated testing of these donors (5 times over a 2-year period for donor H-12; 3 times over a 1-year period for donor NJ) consistently revealed IE1-exon4 CTL positivity, as well as pp65, pp150, and gB negativity. In addition, the profile of CTL specificity remained stable over a 27-month observation time, as exemplified in figure 2 for a highly seropositive individual (H-35) who had specific CTLs for IE1-exon4, pp65, gB, and pp150 (shown only for IE1-exon4 and pp65).
Strong pp65-and IE1-specific CTL activity of bulk cultures reflects similar pp65 and IE1 CTL precursor frequencies. LDAs were done to determine CTL precursor frequencies with PBMC of 2 donors who were repeatedly positive for both pp65 and IE1-exon4 in bulk cultures. Figure 3 shows the results obtained with donor KI (NA titer, 1 : 512). Both the IE1-exon4 and pp65 antigens that were shown to be CTL targets in bulk assays were also detected at similarly high frequencies in LDAs, that is, 566/10 6 PBMC and 699/10 6 PBMC, respectively. Precursor frequencies were also similar for the 2 antigens in donor DF (NA titer, 1 : 512), for whom IE1-exon4-and pp65-specific CTL precursor frequencies were 78/10 6 PBMC and 67/10 6 PBMC, respectively.
HCMV-infected monocytes restimulate both IE1-exon4-and pp65-specific memory CTLs.
To test whether IE1-exon4 presented together with pp65 by the same stimulator cells can restimulate IE1-exon4-specific CTLs, we performed experiments by using effector cells restimulated with HCMV-infected monocytes, that is, cells that express HCMV IE antigens at very low levels [29] [30] [31] . Presentation of the input pp65 to CTLs has also been reported [32] . PBMC from IE1-and pp65-responder donor H-22 were restimulated for 8 days with autologous monocytes infected with the Towne strain of HCMV (MOI, 2-4), and effector cells were tested for IE1-exon4-and pp65-specific CTL activity on autologous and MHC-mismatched Vac-recombinant-infected B-LCL cells. IE1-exon4-and pp65-specific CTL activity was detected (table 2), indicating that both pp65 and IE1-exon4 proteins in monocytes can restimulate CTL memory cells. Effector cells of the same donor restimulated with canarypox-pp65 or canarypox-IE1 lysed cells coinfected with Vac-IE1 and Vac-pp65, indicating that expression of both antigens did not interfere with pp65-or IE1-specific CTL activity (table 2) .
HLA restriction of effector populations. It is generally accepted that activated T cells recognize antigens on the surface of antigen-presenting cells in the context of MHC molecules.
To determine the MHC restriction of the stimulated CTL effectors, cells were tested against a panel of partially HLAmatched and HLA-mismatched targets that express CMV proteins. Figure 4 shows the results obtained from donor H-36, whose cells consistently generated high levels of CTL against pp65, IE1-exon4, and pp150. The pp65-specific CTLs of this donor were directed by the HLA-A2 molecule (figure 4A), because only target cells sharing the A2 allele were lysed. IE1-exon4 was also presented by HLA-A2, because only partially matched target cells sharing HLA-A2 were significantly lysed (figure 4B). The pp150 antigen was presented through the A3 allele ( figure 4C ). Analysis of effectors from donor H-36 on partially HLA-matched target cells of donors sharing alleles other than HLA-A2 or HLA-A3 revealed no pp65-, IE1-exon4-, or pp150-specific lysis of target cells (not shown). The percentage-specific lysis of class I HLA-matched targets was similar to the cytotoxic response against the autologous targets, which suggests a predominance of activated CD8 ϩ cells specific for epitopes presented by the particular HLA allele. Further analysis of selected CTL responders to identify other restricting alleles for pp65-, IE1-exon4-, and pp150-specific CTLs indi- cated that pp65 was presented by A1, A2, A28, A68, B7, and B12/44 alleles; IE1-exon4 was presented by class I HLA alleles A1, A2, A3, B7, B8, B18, and B70; and pp150 was presented by the A3 and B14 alleles (table 3) . Analysis of the restricting allele for gB-specific effector cells identified the class II antigens DR 7, DR15, and DQ 2 or 6 (not shown).
Phenotype of effector cells. The phenotypic characteristics of the pp65-, IE1-exon4-, pp150-, and gB-specific effector cells were examined after depletion of CD4 ϩ and/or CD8 ϩ lymphocytes by use of the respective MAbs plus complement. The subpopulations of the donor effector cells were tested against autologous and MHC-mismatched target cells that express HCMV antigens (figure 5). Depletion of both CD4 ϩ and CD8 ϩ cells completely abrogated killing by the pp65-specific effector cells of donor H-35 (not shown), whereas partial inhibition of specific lysis was observed when either CD8 ϩ or CD4 ϩ cells were depleted (21% and 32% inhibition, respectively; figure 5A). The depletion experiment was repeated 3 times with PBMC of donor H-35 at different time points with similar results, indicating the consistent presence of both CD4 ϩ and CD8 ϩ pp65 effector cells in this donor. To exclude the possibility that the long restimulation in vitro and the addition of IL7 and IL2 favored the growth of CD4
ϩ effector cells, we tested pp65-specific effector cells after a short (6 days) restimulation in vitro without cytokines; phenotypic analysis again revealed mixed effector populations of CD4 ϩ and CD8 ϩ pp65-specific CTLs (data not shown). In contrast, phenotypic analysis of pp65-specific effector cells from another donor (H-36) showed that effector cells were CD8 ϩ , whereas the CD4 ϩ population showed no significant pp65 CTL activity (figure 5B). The CTL response was exerted mainly through CD8 ϩ cells specific for pp65 in an additional donor (H-33), pp150 (donor H-36), and IE1-exon4 (donors H-35 and H-36), because killing of specific target cells after depletion of CD4 ϩ cells was similar to the killing of nondepleted cells (table 4) . gB-specific effector cells, however, lost their activity after CD4 ϩ depletion, but not after CD8 ϩ depletion (donor H-35; table 4). The CD8 ϩ phenotype of IE1-exon4 and pp150 CTLs and the CD4 ϩ phenotype of gB-specific CTLs are consistent with the finding that IE1-exon4 and pp150 are presented by class I alleles, whereas gB is presented by class II alleles.
Discussion
In the present study, we analyzed the HCMV-specific CTL responses of naturally seropositive healthy adult blood donors, comprising different racial groups in different geographic areas with a variety of HLA haplotypes, to determine the prevalence of CTLs specific to various HCMV proteins. We used in vitro cytotoxicity assays, which, to date, remain the best way to examine antigen-stimulated T cells that function as CTLs. All 26 HCMV-seropositive donors mounted specific CTL responses against at least 1 of the HCMV proteins, pp65 or IE1-exon4. In addition, PBMC of some of the seropositive donors revealed CTLs specific to the pp150 and/or gB proteins. However, no pp28-specific CTLs were evidenced, indicating that this protein is not among the immunodominant CTL targets induced by natural HCMV infection. In the experiments described earlier, no obvious differences were observed among racial groups of different geographic areas in the cytotoxic pattern of response to the specific antigens. However, CTL responses did correlate with HCMV NA levels, that is, donors with HCMV NA titers у1 : 128 were more likely to have CTLs positive for multiple CMV antigens, whereas all but 2 of the moderately seropositive donors (HCMV NA titers р1 : 96) had CTLs specific for only pp65 or for pp65 and IE1-exon4 (table 1) , indicating the immunodominance of these 2 antigens. These results also suggest that high NA titers are indicative of a broad spectrum of CTL targets in seropositive donors.
Previous reports have implicated the most abundant protein constituents of the HCMV virion, including the major matrix proteins pp65 and pp150, in CTL induction [32] , and pp65 was identified as the immunodominant CTL target [8, 11] . CTLs have also been shown to recognize exogenously introduced pp65, suggesting that the pp65-specific CTL response acts on virus-infected cells soon after infection and that recognition and cell lysis occur before the onset of viral replication and virion assembly [32] . In a study to determine pp65-specific CTL precursor frequencies, Wills et al. [12] found that all 7 donors tested had CTLs specific for the pp65 protein, and a very high proportion of all HCMV-specific CTLs in any given donor was specific for this single virus protein. In our study, 24 of the 26 H-22  B7  B8  H-33  B70  H-35  A68  B7  H-36  A2  A2  A3  BJ  A1, A2  A1  TK  B12/44  A3  B14  KI  B7  B7, B18  DF  A28  CsK  B18  NJ  B18  BI  A2 NOTE. Effector cells were tested against a panel of partially HLA-matched and HLA-mismatched targets expressing cytomegalovirus proteins.
tested seropositive donors responded with pp65-specific CTLs on in vitro pp65-specific stimulation.
The ubiquity of pp65-specific CTLs in natural HCMV infection suggests that pp65 epitopes can be presented by a wide variety of HLA alleles. Indeed, HLA-B35 [11] , A2, B7, B8, and B35 [12] were identified as pp65 epitope-presenting alleles. In our panel, by using partially HLA-matched target cells, we confirmed and identified alleles A1, A2, A28, A68, B7, and B12/44 presenting pp65.
The pp65-specific effector cells of donor H-35 comprised a mixed population of CD4 ϩ and CD8 ϩ cells, in contrast to the exclusively CD8 ϩ pp65-specific CTLs reported in the literature. The discrepancy might reflect our use of EBV-transformed B lymphoblastoid cells that express both MHC class I and II antigens, in contrast to the use by other investigators of mainly fibroblast target cells that express only MHC class I alleles, which do not enable detection of CD4 ϩ effector cells. We also found donor variability in the phenotype of pp65-specific CTLs, because donors H-36 and H-33 showed only CD8 ϩ effector cells. The percentage of pp65-specific CTL responders with both CD4 ϩ and CD8 ϩ effector cells is unclear. Although the role of CD8
ϩ CTLs in prevention of HCMV disease is well known, the significance of CD4 ϩ effector cells remains unclear. CD4
ϩ CTLs may be effective against latently infected cells with expressed HLA-class II alleles. Studies in the murine CMV (MCMV) model have shown the important contribution of IE1 proteins to MCMV immunity and protection against the disease, and an antigenic peptide has been mapped to IE1 [33] [34] [35] [36] . In 1 study, a high proportion of HCMV-specific CTLs recognized IE1 in 2 donors tested [15] . IE1-specific CTLs were also shown in bulk culture assays [8, 19, 32] , but only in a few donors, and IE1 CTLs were less dominant than pp65 CTLs. Split-well LDA revealed CTLs directed to the IE1 protein in 3 of 5 donors tested, but with significantly lower precursor frequency than that of pp65 CTLs [12] . In a recent study, the frequencies of CD8 ϩ T cells that were directed against IE1 were similar to those directed against pp65 in donors tested by a flow cytometric assay [20] . In our study, IE1-exon4-specific CTLs were nearly as prevalent as pp65-specific CTLs, with similar precursor frequencies. Moreover, this response was maintained over a prolonged period of NOTE. Human cytomegalovirus (HCMV) antigen-specific lysis (‫ע‬SD) is shown at effector-to-target ratios (E : T) of 20 : 1 (*) and of 30 : 1 (**). ND, not done.
a Peripheral blood mononuclear cells (PBMC) were restimulated in vitro with ALVAC-recombinant-infected autologous PBMC, after 8-12 day in vitro culture effector cells were depleted of CD4 ϩ and CD8 ϩ lymphocytes, and their IE1-exon4-, pp65-, pp150-, or gB-specific CTL activity tested as described in Materials and Methods. time, as shown in 10 donors, specifically for donor H-35 who showed IE1-exon4-and pp65-specific lysis of target cells at multiple time points during a 27-month period. This result suggests that detectability of the IE1-exon4-specific CTLs is not a random phenomenon due to a HCMV-reactivation episode or other reasons in some donors, but instead, that IE1-exon4-specific memory CTLs are constantly present in the circulation at detectable levels. The broad spectrum of HLA alleles that present IE1-exon4 (A1, A2, A3, B7, B8, B18, and B70) also supports the high prevalence of IE1-exon4-specific CTLs. Note that 2 donors in our highly seropositive study group had IE1-exon4-specific CTLs but not pp65-, pp150-, or gB-specific effector cells. It is possible that restimulation of individual HCMV-specific CTLs by use of canarypox recombinants enhances the detection of IE1-exon4-specific CTLs, compared with the use of vaccinia-IE1 recombinants or CMV-infected fibroblasts for restimulation. Gilbert et al. [18] reported that pp65 diminishes the IE1-specific CTL activity exerted by IE1-specific CTL clones through a selective abrogation of IE1-peptide presentation by pp65 and its associated kinase activity. In our study, IE1-specific effector cells readily lysed target cells coinfected with Vac-pp65 and Vac-IE1. We did not observe this inhibition in bulk CTL assays where HCMV-infected autologous monocytes were used to restimulate memory CTLs, a situation perhaps more relevant to the in vivo milieu. During HCMV reactivation, IE1 appears earlier than pp65, so that IE1-exon4-specific CTLs may be more effective than pp65-specific CTLs for preventing reactivation. It is not clear why donors H-12 and NJ were negative for pp65-specific CTLs, although both donors have HLA class I alleles (A1 and B7, respectively) that presented pp65 CTL epitopes in other donors. Perhaps HLA A1 and B7 subtypes not identified in this study are involved.
Although 2 of the recently identified 10 CTL epitopes were outside exon4 [20] , inclusion of the full-length IE1 protein in an HCMV vaccine may be problematic because of the known transactivating ability of the HCMV-IE1 proteins [37] . Immunofluorescence analysis to localize the IE1 protein expressed in several forms by a panel of poxvirus recombinants revealed the full-length IE1 gene product predominantly in the nucleus with some cytoplasmic staining, whereas the exon4 protein was found only in the cytoplasm (authors' unpublished observations). Recent data show that IE1-exons2 and 3, but not exon4, are required for binding to p107, a member of a family of cell-cycle inhibitors [38] , and that deletion of exon3 eliminates transactivation by IE1 [39] . Canarypox recombinants that express only exon4 or most of exon3 and exon4 were equivalent in their ability to stimulate IE1-specific CTLs from several HCMV seropositive donors (authors' unpublished observations). Taken together, these observations suggest that expression of the exon4 segment of IE1 eliminates the cellular activation potential associated with IE1 while maintaining most of the CTL epitopes.
gB-specific CTLs were shown in a considerable percentage (33%) of seropositive donors, consistent with previous reports [15, 40] . Hopkins et al. [19] showed gB-specific CTLs in 4 of 7 donors and found that these CTLs were MHC class IIrestricted CD4 ϩ lymphocytes. CD8 ϩ MHC class I-restricted gB-specific CTLs have also been described [8, 32] . In donor H-35, showing gB-specific CTLs in our study, the effector cells were found to be CD4 ϩ lymphocytes, and MHC-class II molecules were identified as the restricting alleles. Together, the evidence indicates that gB-specific CTLs characterized as CD8 ϩ or CD4 ϩ cells are induced by natural HCMV infection and can be shown in in vitro CTL assays. Thus, gB protein can serve as an important inducer of NAs in the majority of the population and as a target of CTL responses in about one-third of the population.
The pp150 protein has also been reported as an immunodominant target for HCMV-specific CTLs [8, 11, 13] . Our studies indicated that pp150 was less dominant than pp65 or IE1-exon4 protein, that is, pp150-specific CTLs were detected in only 30% of seropositive donors, with A3 and B14 alleles presenting pp150 to CD8 ϩ cells. The lack of detectable pp28-specific CTLs in our study might rest in the absence of donors with haplotypes presenting pp28 CTL alleles. Although vaccinia-and canarypox-HCMV recombinants that express pp65, pp150, IE1-exon4, and gB were constructed similarly, we cannot exclude the possibility that processing and presentation of pp28 was not authentic in cells infected with vaccinia-or canarypox-pp28, resulting in pp28-specific negativity in the CTL assays.
Our study shows that (1) regardless of racial and geographical distribution of the population, IE1-exon4 protein is nearly as prevalent a CTL target as is pp65; (2) gB-and pp150-specific CTLs are detectable in about one-third of the seropositive donors; and (3) pp28 is not an immunodominant CTL target. These results, as well as our findings on the phenotype of HCMV protein-specific CTLs and the presenting alleles, may provide some insight into the immunology of HCMV infection and may contribute to the design of a vaccine that elicits effective CTL responses against both acutely infected cells, which express nonstructural IE1 and structural antigens, and latently infected cells during reactivation, in which nonstructural antigens are expressed earlier than structural proteins.
